New drug cocktail aims to shrink Hard-to-Treat solid tumors

NCT ID NCT07140393

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and see if the combination helps shrink tumors. About 120 adults aged 18 to 75 with measurable tumors and good overall health are eligible to participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4508
What this could lead to: If successful, this could provide a new combination treatment option for people with advanced solid tumors that are not responding to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or could cause unexpected side effects. Results may not apply to all solid tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Science
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.